FDA Warns Swiss Company
Laboratoire Sintyl S.A. received an FDA warning letter for CGMP quality violations.
FDA issued a warning letter to Laboratoire Sintyl S.A. after a June 2016 inspection of the company’s Geneva facility. The company was cited for current good manufacturing practice (CGMP) violations including failing to test the strength of active ingredients.
During the inspection, FDA found the company had failed to establish quality control unit responsibilities and procedures for reviewing out-of-specification results and customer complaints. Investigators were told that the company had no independent quality unit.
Specific quality issues that were observed included a failure to test finished batches of drug product for identity and strength of active ingredients and a failure to identify components sourced from suppliers. A lack of proper cleaning and maintenance was also observed.
FDA recommended the company engage a qualified consultant to help meet CGMP requirements. The agency stated it may refuse admission of drug products that have not been manufactured under CGMP guidelines.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
